Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].

Gynecol Oncol Rep

Published: May 2021

The text is a notice indicating that there is a correction to an article with the DOI reference 10.1016/j.gore.2020.100648.
The correction aims to address inaccuracies or errors found in the original publication.
Readers are encouraged to refer to the updated information to ensure they have the most accurate understanding of the research.

[This corrects the article DOI: 10.1016/j.gore.2020.100648.].

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169695	PMC
http://dx.doi.org/10.1016/j.gore.2021.100740	DOI Listing

Publication Analysis

corrigendum "long-term

"long-term follow-up

follow-up phase

phase trial

trial involving

involving advanced

advanced ovarian

ovarian cancer

cancer patients

patients treated

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!